Diffuse High Intensity PD–L1 Staining in Thymic Epithelial Tumors

Slides:

Advertisements

Similar presentations

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Advertisements

Comprehensive Pathological Analyses in Lung Squamous Cell Carcinoma: Single Cell Invasion, Nuclear Diameter, and Tumor Budding Are Independent Prognostic.

Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer

E13-01: Insights into thymic epithelial tumor: pathology

Expression of PD-L1 in mastocytosis

ALK FISH and IHC: You Cannot Have One without the Other

Y-L Chang, MD, C-T Wu, MD, Y-C Lee, MD, PhD

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Determinants of Complete Resection of Thymoma by Minimally Invasive and Open Thymectomy: Analysis of an International Registry Bryan M. Burt, MD, Xiaopan.

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer Hidenobu Ishii, MD,

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Co-Overexpression of Cyclooxygenase-2 and Microsomal Prostaglandin E Synthase-1 Adversely Affects the Postoperative Survival in Non-small Cell Lung Cancer

Electronic Updates for JTO Readers

Vamsidhar Velcheti, MD, David L. Rimm, MD, PhD, Kurt A

Muhammad Umair Khawar, MD, Bhaskar Bhardwaj, MD, Himanshu Bhardwaj, MD

An Unusual Presentation of Malignant Pleural Mesothelioma

Keith M. Kerr, MBChB, FRCPath, Ming-Sound Tsao, MD, PhD, Andrew G

A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer W Jeffrey Petty, MD, Sommer N.

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Surgical Management of Recurrent Thymic Epithelial Tumors: A Retrospective Analysis Based on the Japanese Nationwide Database Tetsuya Mizuno, MD, Meinoshin.

Alterations of the Immune System in Thymic Malignancies

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Potential Role of Platelet-Derived Growth Factor Receptor Inhibition Using Imatinib in Combination with Docetaxel in the Treatment of Recurrent Non-small.

“Pseudoprogression” of Pulmonary Pleomorphic Carcinoma during Nivolumab Therapy Kentaro Ito, MD, Osamu Hataji, MD, Koji Katsuta, MD, Tetsu Kobayashi,

The Oncofetal Protein IMP3: A Useful Marker to Predict Poor Clinical Outcome in Neuroendocrine Tumors of the Lung Alessandro Del Gobbo, MD, Valentina.

Standard Outcome Measures for Thymic Malignancies

Detection of Human Polyomavirus 7 in Human Thymic Epithelial Tumors

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer Antonio Calles, MD, Xiaoyun Liao, MD,

Clinical Characteristics and Outcomes for Patients With Thymic Carcinoma: Evaluation of Masaoka Staging Anya M. Litvak, MD, Kaitlin Woo, MS, Sara Hayes,

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Relevance of Platinum-Sensitivity Status in Relapsed/Refractory Extensive-Stage Small- Cell Lung Cancer in the Modern Era: A Patient-Level Analysis of.

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J

Michael A. den Bakker, MD, PhD, Anja C

Lung Cancer Patients with Germline Mutations Detected by Next-Generation Sequencing and/or Liquid Biopsy Takehito Shukuya, MD, PhD, Sandipkumar Patel,

LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD- 1/PD-L1 and Tumor-Infiltrating Lymphocytes Yayi He, MD, PhD, Hui.

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 Paul J. Hesketh, MD, Rogerio C. Lilenbaum,

Development of the International Thymic Malignancy Interest Group International Database: An Unprecedented Resource for the Study of a Rare Group of Tumors

The Prognostic Significance of Focal Adhesion Kinase Expression in Stage I Non– Small-Cell Lung Cancer Grace K. Dy, MD, Lourdes Ylagan, MD, Saraswati.

Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer

Loss of p16INK4A Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas Scott W. Aesif, MD,

Expression and Mutational Status of c-kit in Thymic Epithelial Tumors

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

Mitotic Inhibitors Journal of Thoracic Oncology

Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma Kyuichi Kadota, MD, PhD, Jun-ichi Nitadori, MD, PhD, Hideki Ujiie, MD, Daniel.

Aglaya G. Iyevleva, MD, PhD Journal of Thoracic Oncology

Impact of Non–Small-Cell Lung Cancer-Not Otherwise Specified Immunophenotyping on Treatment Outcome Luisella Righi, MD, PhD, Tiziana Vavalà, MD, Ida.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Tumor-Stroma Ratio Is an Independent Predictor for Survival in Esophageal Squamous Cell Carcinoma kai Wang, MD, Wei Ma, MD, Jianbo Wang, MD, Liang Yu,

A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43– 9006) in Previously Treated Non–Small-Cell Lung Cancer Patients: Eastern.

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011) Ellen.

Comprehensive Pathological Analyses in Lung Squamous Cell Carcinoma: Single Cell Invasion, Nuclear Diameter, and Tumor Budding Are Independent Prognostic.

Phase I Study of Lenalidomide in Solid Tumors

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer: Still Following the Right TRAIL? Emmet E. McGrath, MB, PhD Journal of Thoracic.

International Thymic Malignancies Interest Group: A Way Forward

Pruritus as a Paraneoplastic Symptom of Thymoma

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Epidemiology of Thymoma and Associated Malignancies

An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and.

A B3 Type-Thymoma in a 7-Year-Old Child with Myasthenia Gravis

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

A Review of First-Line Treatment for Small-cell Lung Cancer

Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database Sukhmani.

Presentation transcript:

Diffuse High Intensity PD–L1 Staining in Thymic Epithelial Tumors Sukhmani K. Padda, MD, Jonathan W. Riess, MD, MS, Erich J. Schwartz, MD, PhD, Lu Tian, PhD, Holbrook E. Kohrt, MD, PhD, Joel W. Neal, MD, PhD, Robert B. West, MD, PhD, Heather A. Wakelee, MD Journal of Thoracic Oncology Volume 10, Issue 3, Pages 500-508 (March 2015) DOI: 10.1097/JTO.0000000000000429 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Magnification ×300. Panel A Type B2 thymoma, panel B normal thymus, and panel C micronodular thymoma with lymphoid stroma. Stains include H&E (left column), CK5/6 (middle column) highlighting thymic epithelial cells, and PD-L1 (right column). In panels A and B, only the epithelial cells stain for PD-L1. Panel C PD-L1 staining of both thymic epithelial cells and lymphocytes. Panels A–C Strong (IHC 3), weak (IHC 2), and intermediate (IHC 3) PD-L1 staining, respectively. H&E, hematoxylin and eosin; PD-L1, programmed death receptor ligand-1; IHC, immunohistochemistry. Journal of Thoracic Oncology 2015 10, 500-508DOI: (10.1097/JTO.0000000000000429) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 PD-L1 intensity and outcomes (A) OS with stratification by age lesser than 50 years old, (B) OS with stratification by age greater than or equal to 50 years old, (C) EFS. PD-L1high TETs demonstrate no difference in EFS and OS in an unadjusted analysis. When adjusted for age and sex, PD-L1 high TETs had a statistically significant worse OS, with age being the most important adjustment. PD-L1 high TETs also had a trend for worse EFS when adjusted for age and sex, with adjustment favoring woman. OS events: PD-L1high, 10 events of 47 and PD-L1low, 5 events of 22. EFS events: PD-L1high, 18 events of 44 and PD-L1low, 5 events of 20. PD-L1, programmed death receptor ligand-1; OS, overall survival; EFS, event-free survival; TET, thymic epithelial tumor. Journal of Thoracic Oncology 2015 10, 500-508DOI: (10.1097/JTO.0000000000000429) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions